StageZero Life Sciences Ltd.
SZLSF · OTC
9/30/2024 | 6/30/2024 | 3/31/2024 | 9/30/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.08 | -0.01 | 0.00 | -0.01 |
| FCF Yield | 0.21% | -4.24% | -1.87% | 0.96% |
| EV / EBITDA | -20.95 | -6.40 | -20.44 | -8.46 |
| Quality | ||||
| ROIC | 4.09% | 8.40% | 4.03% | 10.65% |
| Gross Margin | -13.93% | 2.00% | 54.08% | 22.59% |
| Cash Conversion Ratio | -0.03 | 0.10 | 0.24 | -0.06 |
| Growth | ||||
| Revenue 3-Year CAGR | -21.80% | -14.46% | -17.59% | -21.37% |
| Free Cash Flow Growth | 116.30% | 31.99% | 0.00% | 577.76% |
| Safety | ||||
| Net Debt / EBITDA | -6.29 | -3.72 | -5.27 | -1.79 |
| Interest Coverage | -7.47 | -13.20 | -7.72 | -28.33 |
| Efficiency | ||||
| Inventory Turnover | 10.93 | 16.94 | 10.58 | 25.57 |
| Cash Conversion Cycle | -604.09 | -875.15 | -1,456.19 | -558.93 |